^
    17d
    Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas (clinicaltrials.gov)
    P1, N=42, Recruiting, St. Jude Children's Research Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • fludarabine IV • B7-H3 CAR-T
    18d
    B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma (clinicaltrials.gov)
    P1, N=14, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    19d
    Phase I Study of TX103 CAR-T Cells in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=85, Recruiting, Tcelltech Inc.
    New P1 trial
    1m
    A single-arm, dose-escalation, exploratory clinical study to evaluate the tolerability, safety, pharmacokinetic profile and preliminary efficacy of MT027 cell injection in patients with malignant solid tumours metastatic to the brain, brain (spinal) membrane and spinal cord (ChiCTR2500107346)
    P=N/A, N=9, Recruiting, FuJIan SanBo FuNeng Brain Hospital; FuJIan SanBo FuNeng Brain Hospital
    New trial
    |
    CD276 (CD276 Molecule)
    |
    MT027
    1m
    Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas (clinicaltrials.gov)
    P1, N=42, Not yet recruiting, St. Jude Children's Research Hospital
    New P1 trial
    |
    cyclophosphamide • fludarabine IV • B7-H3 CAR-T
    1m
    GPC2-CAR T cells have potent preclinical activity against orthotopic medulloblastoma xenografts. (PubMed, Mol Ther Oncol)
    GPC2-CARs lead to significant in vivo tumor regression in orthotopic tumor models via intravenous or intraventricular administration route and had equivalent activity to the B7-H3-CAR against D283 and enhanced activity than GD2-CAR in both models in vivo. T cell kinetic studies revealed that GPC2-CAR T cells home to the area of the primary tumor, expand, and upregulate genes critical for cytotoxicity and T cell homing. These results provide a preclinical rationale for including children with GPC2+ MB in our upcoming clinical GPC2-CAR T cell trial.
    Preclinical • Journal
    |
    CD276 (CD276 Molecule)
    |
    B7-H3 CAR-T
    2ms
    B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma (clinicaltrials.gov)
    P1, N=14, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P1 trial • First-in-human
    3ms
    B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme (clinicaltrials.gov)
    P1, N=39, Recruiting, Stanford University | Trial completion date: Aug 2025 --> Aug 2026 | Trial primary completion date: Aug 2025 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    IDH wild-type
    3ms
    Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors (clinicaltrials.gov)
    P1, N=48, Recruiting, St. Jude Children's Research Hospital | N=36 --> 48
    Enrollment change
    |
    CD276 (CD276 Molecule)
    |
    B7-H3 CAR-T
    4ms
    Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection (clinicaltrials.gov)
    P1/2, N=25, Recruiting, Dushu Lake Hospital Affiliated to Soochow University | Suspended --> Recruiting | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Enrollment open • Trial completion date • Trial primary completion date
    |
    CD276 (CD276 Molecule)
    |
    QH104
    4ms
    UTAA06 Injection for Treatment of Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P1, N=10, Completed, Peking University | Recruiting --> Completed
    Trial completion
    |
    UTAA06
    5ms
    B7-H3 CAR T-cells are effective against ependymomas, but limited by tumor size and immune response. (PubMed, Clin Cancer Res)
    Our results support ongoing clinical evaluation of B7-H3.CAR T-cells for EPNs and provide model systems for further studying determinants of anti-EPN CAR T-cell treatment efficacy and resistance.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • CD276 (CD276 Molecule) • CCL2 (Chemokine (C-C motif) ligand 2)
    |
    B7-H3 CAR-T